Cancer Reports
·
2022
·Vol. 6
·期 2
·e1688
·
IF 0
Ying Liang,Yan Liu,Pin Zhang,Mengxin Zhang,Bang Du,Weyland Cheng,Zhidan Yu,Lifeng Li,Huanmin Wang,Guangjun Hou,Xianwei Zhang,Wancun Zhang
The postoperative recurrence of neuroblastoma (NB) patients is an essential reason for the high mortality of NB due to the lack of early, non-invasive, and dynamic strategies for monitoring NB recurrence. Therefore, whether the plasma circulating cell-free MYCN gene as an indicator for monitoring of NB recurrence was systematically evaluated. The MYCN copy number and NAGK (reference gene) copy number (M/N) ratio in plasma and corresponding tumor tissues of NB patients was detected using an economical, sensitive, and specific single-tube dual RT-PCR approach developed in this study. The plasma M/N ratio of the MYCN gene amplification (MNA) group ( N = 25, median M/N ratio = 4.90) was significantly higher than that of the non-MNA group ( N = 71, median M/N ratio = 1.22), p < .001. The M/N ratio in NB plasma ( N = 60) was positively correlated with the M/N ratio in NB tumor tissue ( N = 60), with a correlation coefficient of 0.9496. In particular, the results of dynamic monitoring of postoperative plasma M/N ratio of NB patients showed that an abnormal increase in M/N ratio could be detected 1–2 months before recurrence in NB patients. In summary, the single-tube double RT-PCR approach can be used to quantitatively detect MYCN copy number. The copy number of MYCN in the tissue and plasma of NB patients is consistent with each other. More importantly, the circulating cell-free MYCN gene of NB patients can be used as a monitoring indicator for early, non-invasive, and dynamic monitoring of NB recurrence.
研究领域:
肿瘤学
·
分子生物学
·
遗传学
✓ 已验证
DOI
PubMed
Nature Communications
·
2024
·Vol. 15
·期 1
·1-17
·
IF 14.7
Wu Min,Wang Tingting,Ji Nan,Lu Ting,Yuan Ran,Wu Lingxiang,Zhang Junxia,Li Mengyuan,Cao Penghui,Zhao Jiarui,Li Guanzhang,Li Jianyu,Li Yu,Tang Yujie,Gao Zhengliang,Wang Xiuxing,Cheng Wen,Ge Ming,Cui Gang,Li Rui,Wu Anhua,You Yongping,Zhang Wei,Wang Qianghu,Chen Jian
Glioblastoma (GBM) is the most common brain tumor and remains incurable. Primary GBM cultures are widely used tools for drug screening, but there is a lack of genomic and pharmacological characterization for these primary GBM cultures. Here, we collect 50 patient-derived glioma cell (PDGC) lines and characterize them by whole genome sequencing, RNA sequencing, and drug response screening. We identify three molecular subtypes among PDGCs: mesenchymal (MES), proneural (PN), and oxidative phosphorylation (OXPHOS). Drug response profiling reveals that PN subtype PDGCs are sensitive to tyrosine kinase inhibitors, whereas OXPHOS subtype PDGCs are sensitive to histone deacetylase inhibitors, oxidative phosphorylation inhibitors, and HMG-CoA reductase inhibitors. PN and OXPHOS subtype PDGCs stably form tumors in vivo upon intracranial transplantation into immunodeficient mice, whereas most MES subtype PDGCs fail to form tumors in vivo. In addition, PDGCs cultured by serum-free medium, especially long-passage PDGCs, carry MYC/MYCN amplification, which is rare in GBM patients. Our study provides a valuable resource for understanding primary glioma cell cultures and clinical translation and highlights the problems of serum-free PDGC culture systems that cannot be ignored.
研究领域:
肿瘤学
·
基因组学
·
药理学
·
神经科学
✓ 已验证
DOI
PubMed
高影响因子
危险品化学品经营许可证（带存储）